Evidence map›Paper›PMID 41540143›Full record

ArticleEuropean journal of human genetics : EJHG2026

Integration of multi-omics data uncovers novel germline susceptibility candidates in early-onset colorectal cancer.

Anael López-Novo, Jorge Amigo, Andrés Dacal, David Remedios-Espino, Joaquín Cubiella, María Victoria Álvarez-Sánchez, María Jesús Ladra-González, Fernando Fernández-López, Ana Álvarez-Castro, Silvia Carlés and 7 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anael López-NovoFundación Pública Galega de Medicina Xenómica (SERGAS), Instituto de Investigación Sanitaria de Santiago, GMX-University of Santiago de Compostela, Santiago de Compostela, Spain. anaellopeznovo@gmail.com.ORCID http://orcid.org/0000-0001-7371-9524
Jorge AmigoFundación Pública Galega de Medicina Xenómica (SERGAS), Instituto de Investigación Sanitaria de Santiago, GMX-University of Santiago de Compostela, Santiago de Compostela, Spain.
Andrés DacalDepartment of Gastroenterology, Hospital Lucus Augusti, Lugo, Spain.
David Remedios-EspinoDepartment of Gastroenterology, CHUO, CIBEREHD, Ourense, Spain.
Joaquín CubiellaDepartment of Gastroenterology, CHUO, CIBEREHD, Ourense, Spain.ORCID http://orcid.org/0000-0002-9994-4831
María Victoria Álvarez-SánchezDepartment of Gastroenterology, CHOP, Pontevedra, Spain.
María Jesús Ladra-GonzálezDigestive Surgery Department, Coloproctology Unit, CHUS, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0001-5919-3239
Fernando Fernández-LópezDigestive Surgery Department, Coloproctology Unit, CHUS, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0001-6132-9641
Ana Álvarez-CastroDepartment of Gastroenterology, CHUS, Santiago de Compostela, Spain.
Silvia CarlésCancer Predisposition and Biomarkers Lab, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0002-5878-5045
José Manuel Cameselle-TeijeiroDepartment of Pathology, CHUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Miriam CuatrecasasDepartment of Pathology, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBEREHD and Tumour Bank-Biobank, Barcelona, Spain.ORCID http://orcid.org/0000-0003-3063-0110
Francesc BalaguerDepartment of Gastroenterology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBEREHD, Hospital Clínic, Barcelona, Spain.
Sergi Castellví-BelDepartment of Gastroenterology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBEREHD, Hospital Clínic, Barcelona, Spain.ORCID http://orcid.org/0000-0003-1217-5097
Ceres Fernández-RozadillaCancer Predisposition and Biomarkers Lab, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain.
Ángel CarracedoFundación Pública Galega de Medicina Xenómica (SERGAS), Instituto de Investigación Sanitaria de Santiago, GMX-University of Santiago de Compostela, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0001-7330-4804
Clara Ruiz-PonteFundación Pública Galega de Medicina Xenómica (SERGAS), Instituto de Investigación Sanitaria de Santiago, GMX-University of Santiago de Compostela, Santiago de Compostela, Spain. clara.ruiz.ponte@usc.es.ORCID http://orcid.org/0000-0002-2200-0162

Funding

Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) INT21/00040Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI17/00509Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI17/00878Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI20/00113Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI20/00226
6 · The paper itself

Abstract

Colorectal cancer (CRC) is increasingly diagnosed in individuals under 50 years of age, yet the underlying genetic predisposition remains largely unexplained, particularly in mismatch repair (MMR)-proficient cases. This study aimed to identify novel hereditary CRC susceptibility genes by integrating germline and tumour whole-exome sequencing (WES) with transcriptomic profiling across a cohort of early-onset CRC (EOCRC) patients. Tumours were categorised using Consensus Molecular Subtypes (CMS) classification and analysed for mutational signature and burden. We used a novel 'All vs One' multi-omic integration approach to identify loss-of-function rare germline variants with concordant gene expression alterations in tumour tissue. Five candidate genes (ADCY4, NOXO1, CDHR2, ARHGAP10, EEF2K) were prioritised based on this approach and potential biological relevance in CRC. These findings highlight the molecular heterogeneity of EOCRC and demonstrate the utility of multi-omic approaches in refining germline variant interpretation. Integrating tumour transcriptomics enhances gene discovery efforts and supports a more comprehensive understanding of CRC heritability in younger individuals.

Indexed as

Colorectal NeoplasmsGenetic Predisposition to DiseaseGerm-Line MutationAdultAge of OnsetExome SequencingFemaleHumansMaleMiddle AgedMultiomics

Identifiers

PMID41540143
PMCPMC13550470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.